SNNA - Your Daily Pharma Scoop: ESPR Phase 3 Positive FDA Rejects Volanesorsen Ozempic Succeeds
Stocks in News: ESPR
Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study
Discussion:
Positive top-line results from the pivotal Phase 3 trial of Esperion’s (ESPR) bempedoic acid/ezetimibe combination pill study (1002-053) has been reported by the company. This trial was conducted in a 380 high-risk patient group with maximally tolerated statins. The trial evaluated the efficacy and safety of the bempedoic acid 180 mg/ezetimibe 10 mg combination pill compared to bempedoic acid, ezetimibe or placebo.
The trial met its key efficacy endpoint. The combination therapy reduced LDL-C